Skip to content

Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals

Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01363869
Enrollment
30
Registered
2011-06-02
Start date
2011-06-30
Completion date
2013-03-31
Last updated
2013-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout, Hyperuricemia

Keywords

hyperuricemia, gout, uric acid, xanthine oxidase inhibitor, green tea, catechins, antioxidant

Brief summary

Green tea has been extensively investigated for several potential health benefits. Previous studies have suggested that green tea may lower serum uric acid level in human. The purpose of this study is to investigate uric-lowering properties of green tea in healthy individuals.

Detailed description

Elevated serum uric acid is related to the risk of development of gout, the most common inflammatory arthritis in men. Allopurinol, a xanthine oxidase inhibitor, is one of the uric-lowering agents commonly used in patients suffering from recurrent and chronic gout. Nevertheless, its use is limited by adverse effects and serious allergic reaction in some patients. Green tea is one of the most frequently consumed beverages, particularly in Japan. Green tea contains high level of catechins, in which Epigallocatechin gallate (EGCG) is the most abundant compound among other types of catechins. Antioxidant effect contributes to various potential health benefits of green tea. Several in-vitro studies have found that green tea inhibits xanthine oxidase activity and subsequently decreases reactive oxygen species (ROS) and uric acid production. We therefore would like to investigate the hypouricemic effects of green tea. The study consists of three periods with a total duration of four weeks. The first week is the control period. The following two weeks is the interventional period and the last week is the follow up period. Thirty healthy participants will be randomly assigned into three experimental groups, receiving 2 gm/day, 4 gm/day and 6 gm/day (in capsule, two times after meal) of green tea extract during interventional period. Blood and urine samples will be taken at the beginning and at the end of each study period.

Interventions

DIETARY_SUPPLEMENTgreen tea extracts 2 gm/day

Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days. Total dosage is 2 grams per day.

DIETARY_SUPPLEMENTgreen tea extracts 4 gm/day

Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days. Total dosage is 4 grams per day.

DIETARY_SUPPLEMENTgreen tea extracts 6 gm/day

Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days. Total dosage is 6 grams per day.

Sponsors

Chiang Mai University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 18 years or older * Healthy individuals * Normal renal and liver function from blood tests

Exclusion criteria

* Presence of co-morbidity or currently ill * Currently using any medication or nutritional supplement product that may affect serum uric acid level * Serum creatinine higher than 1.5 mg/dl * Abnormal serum Aspartate aminotransferase (AST) and/or Alanine transaminase (ALT) * Greater than 15% change in serum uric acid during control period

Design outcomes

Primary

MeasureTime frame
serum uric acid4 weeks (prior to, immediately after and 7 days after intervention)

Secondary

MeasureTime frameDescription
urinary uric acid excretion4 weeks (prior to, immediately after and 7 days after intervention)
serum antioxidant activity4 weeks (prior to, immediately after and 7 days after intervention)
serum EGCG level1 week (immediately after and 7 days after intervention)Measurements of serum level of epigallocatechin gallate (EGCG)
Adverse events4 week (prior to, immediately after and 7 days after intervention)Adverse events during 4-week study

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026